Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during the specified period [1][2]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1]. Allegations - The complaint alleges that RxSight failed to disclose significant adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - It is claimed that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, with the CEO citing adoption challenges as a primary reason for the sales stall [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].